Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M.R. Janes
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Angioimmunoblastic T-Cell Lymphoma: A Rare Subtype of Peripheral T-Cell Lymphoma
Clinical Case Reports
Medicine
PRELIMINARY RESULTS OF ASTX660, a NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-Cell LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Conjunctival Angioimmunoblastic T-Cell Lymphoma
Ocular Oncology and Pathology
Nursing
Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Targeting the Peripheral T-Cell Lymphoma (Ptcl) Epigenome With Oral 5-Azacytidine and Romidepsin: Results and Clinical-Molecular Correlations From a Phase 2 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Correction To: Multicenter Phase 1/2 Study of Forodesine in Patients With Relapsed Peripheral T Cell Lymphoma
Annals of Hematology
Medicine
Hematology
